CN108289943B - 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽 - Google Patents

在肿瘤细胞中拮抗wnt信号传递的双互补位多肽 Download PDF

Info

Publication number
CN108289943B
CN108289943B CN201680071043.6A CN201680071043A CN108289943B CN 108289943 B CN108289943 B CN 108289943B CN 201680071043 A CN201680071043 A CN 201680071043A CN 108289943 B CN108289943 B CN 108289943B
Authority
CN
China
Prior art keywords
ser
gly
arg
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680071043.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108289943A (zh
Inventor
V·齐恩阿拉
K-P·权凯莱
M-A·比斯
K·克罗米
S·泰伦斯
B·斯塔布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alberix Corp
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN108289943A publication Critical patent/CN108289943A/zh
Application granted granted Critical
Publication of CN108289943B publication Critical patent/CN108289943B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680071043.6A 2015-12-04 2016-12-02 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽 Active CN108289943B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04
EP15197999.4 2015-12-04
PCT/EP2016/079575 WO2017093478A1 (en) 2015-12-04 2016-12-02 Biparatopic polypeptides antagonizing wnt signaling in tumor cells

Publications (2)

Publication Number Publication Date
CN108289943A CN108289943A (zh) 2018-07-17
CN108289943B true CN108289943B (zh) 2023-06-20

Family

ID=54782606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071043.6A Active CN108289943B (zh) 2015-12-04 2016-12-02 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽

Country Status (34)

Country Link
US (2) US10597449B2 (enExample)
EP (2) EP3383425B1 (enExample)
JP (2) JP6728355B2 (enExample)
KR (1) KR102802241B1 (enExample)
CN (1) CN108289943B (enExample)
AR (1) AR106949A1 (enExample)
AU (1) AU2016363787B2 (enExample)
BR (1) BR112018010537A2 (enExample)
CA (1) CA3006235A1 (enExample)
CL (1) CL2018001384A1 (enExample)
CO (1) CO2018005680A2 (enExample)
CY (1) CY1123454T1 (enExample)
DK (1) DK3383425T3 (enExample)
EA (1) EA201891331A1 (enExample)
ES (1) ES2821099T3 (enExample)
HR (1) HRP20201528T1 (enExample)
HU (1) HUE051777T2 (enExample)
IL (1) IL259119B (enExample)
LT (1) LT3383425T (enExample)
MA (2) MA54648A (enExample)
MX (1) MX380414B (enExample)
MY (1) MY200933A (enExample)
NZ (1) NZ742037A (enExample)
PE (1) PE20181515A1 (enExample)
PH (1) PH12018501155B1 (enExample)
PL (1) PL3383425T3 (enExample)
PT (1) PT3383425T (enExample)
RS (1) RS60823B1 (enExample)
SA (1) SA518391728B1 (enExample)
SG (1) SG11201804510PA (enExample)
SI (1) SI3383425T1 (enExample)
TW (1) TWI734719B (enExample)
UA (1) UA122079C2 (enExample)
WO (1) WO2017093478A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968742T3 (es) 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
AR106949A1 (es) 2015-12-04 2018-03-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR102717656B1 (ko) * 2017-05-31 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
EP3664830A4 (en) 2017-08-07 2020-07-01 The Regents of the University of California RISK-FREE CELL THERAPEUTIC GENERATION PLATFORM
JP2021504492A (ja) 2017-11-29 2021-02-15 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 癌治療のための組成物および方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
DK3820906T3 (da) * 2018-07-05 2025-12-15 Surrozen Operating Inc Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3947455A1 (en) 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy
CN113646048A (zh) 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法
EP3966242A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
CN114402079A (zh) * 2019-05-08 2022-04-26 印希彼有限公司 Cd123靶向免疫疗法
CN118909117A (zh) * 2019-08-14 2024-11-08 安托拉诊疗公司 与lrp6蛋白结合的抗体及使用方法
EP4013791A4 (en) * 2019-08-14 2024-01-24 Modmab Therapeutics Inc. LRP5 PROTEIN-BINDING ANTIBODIES AND METHODS OF USE THEREOF
EP4034564A4 (en) 2019-09-23 2023-12-13 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
US20240391997A1 (en) * 2021-07-16 2024-11-28 Brightpath Biotherapeutics Co., Ltd. Anti-tim-3 antigen antibody or antibody derivative, and use thereof
AU2023421423A1 (en) * 2023-01-05 2025-07-17 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646563A (zh) * 2000-04-17 2005-07-27 科里克萨有限公司 治疗和诊断乳腺癌的组合物与方法
WO2011119661A1 (en) * 2010-03-24 2011-09-29 Genentech, Inc. Anti-lrp6 antibodies
WO2011138391A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2014029752A1 (en) * 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP5113523B2 (ja) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
US7563619B2 (en) * 2006-05-30 2009-07-21 Van Andel Research Institute Mammary stem cell marker
US8177435B2 (en) 2006-06-08 2012-05-15 Nsk Ltd. Manufacturing method of a drawn cup needle roller bearing having seal ring
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
EP2567709B1 (en) 2007-11-02 2017-12-27 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
WO2010127216A2 (en) 2009-05-01 2010-11-04 Telcodia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
WO2012054565A1 (en) * 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
AR106949A1 (es) 2015-12-04 2018-03-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646563A (zh) * 2000-04-17 2005-07-27 科里克萨有限公司 治疗和诊断乳腺癌的组合物与方法
WO2011119661A1 (en) * 2010-03-24 2011-09-29 Genentech, Inc. Anti-lrp6 antibodies
WO2011138391A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2014029752A1 (en) * 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies

Also Published As

Publication number Publication date
IL259119B (en) 2022-04-01
HUE051777T2 (hu) 2021-03-29
EP3383425A1 (en) 2018-10-10
CA3006235A1 (en) 2017-06-08
DK3383425T3 (da) 2020-09-28
BR112018010537A2 (pt) 2018-11-13
SG11201804510PA (en) 2018-06-28
PT3383425T (pt) 2020-10-07
PH12018501155A1 (en) 2019-01-28
CL2018001384A1 (es) 2018-09-14
SI3383425T1 (sl) 2020-11-30
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
WO2017093478A1 (en) 2017-06-08
CY1123454T1 (el) 2022-03-24
US20170174762A1 (en) 2017-06-22
ES2821099T3 (es) 2021-04-23
NZ742037A (en) 2025-07-25
AU2016363787B2 (en) 2023-02-02
TWI734719B (zh) 2021-08-01
US20200199222A1 (en) 2020-06-25
HK1255725A1 (en) 2019-08-23
CO2018005680A2 (es) 2018-06-12
MX380414B (es) 2025-03-12
MA43368B1 (fr) 2020-09-30
JP2019506841A (ja) 2019-03-14
EA201891331A1 (ru) 2018-12-28
IL259119A (en) 2018-06-28
US11952418B2 (en) 2024-04-09
KR102802241B1 (ko) 2025-05-07
KR20180081825A (ko) 2018-07-17
LT3383425T (lt) 2020-10-12
PE20181515A1 (es) 2018-09-21
JP2020178701A (ja) 2020-11-05
AR106949A1 (es) 2018-03-07
EP3383425B1 (en) 2020-07-15
US10597449B2 (en) 2020-03-24
EP3797790A1 (en) 2021-03-31
MA54648A (fr) 2021-11-10
CN108289943A (zh) 2018-07-17
MX2018006760A (es) 2018-08-01
TW201731868A (zh) 2017-09-16
PL3383425T3 (pl) 2021-01-11
HRP20201528T1 (hr) 2020-12-11
SA518391728B1 (ar) 2022-03-28
AU2016363787A1 (en) 2018-05-17
UA122079C2 (uk) 2020-09-10
RS60823B1 (sr) 2020-10-30
MA43368A (fr) 2018-10-10
JP6728355B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
CN108289943B (zh) 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽
US12285493B2 (en) Polypeptides antagonizing Wnt signaling in tumor cells
HK40040630A (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
HK1255725B (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках
EA040170B1 (ru) БИПАРАТОПНЫЕ ПОЛИПЕПТИДЫ-АНТАГОНИСТЫ ПЕРЕДАЧИ СИГНАЛА Wnt В ОПУХОЛЕВЫХ КЛЕТКАХ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250319

Address after: Belgian Weiner de

Patentee after: Alberix Corp.

Country or region after: Belgium

Address before: Germany

Patentee before: BOEHRINGER INGELHEIM INTERNATIONAL GmbH

Country or region before: Germany